### 1. Clinical Rationale and Unmet Need
Epilepsy affects approximately 50 million people globally, with 30% of patients presenting drug-resistant phenotypes. These patients face a significantly higher risk of mortality due to status epilepticus (prolonged seizures) and seizure clusters (recurrent seizures without full recovery). In these acute scenarios, the clinical priority shifts from long-term prophylaxis to rapid intervention to prevent irreversible neuronal damage. CLUSTREL addresses this critical gap by enabling rapid and precise drug administration at the onset of a seizure, ensuring immediate suppression without the delays or variability associated with current intranasal, oral, or rectal emergency therapies.
### 2. Technological Innovation: Graphene-Based Electro-Responsive Platforms
The heart of CLUSTREL leverages the unique physicochemical properties of graphene, a 2D nanomaterial that functions as both a high-capacity drug carrier and an electro-responsive actuator.
* **Molecular Interface**: Active pharmaceutical ingredients (specifically benzodiazepines such as midazolam or diazepam) are loaded onto graphene oxide surfaces via non-covalent $\pi-\pi$ interactions.
* **Electrochemical Actuation**: A mild electrical stimulus (~+1.2 V) triggers an electrochemical reaction that weakens these non-covalent bonds, facilitating on-demand release.
* **Kinetic Precision**: The system is engineered to deliver a full therapeutic dose (0.5–2 mg) within a clinically optimal window of less than 2 minutes.
### 3. Device Engineering and Safety
CLUSTREL is designed as an intelligent, non-invasive oral reservoir integrated into a structure similar to a dental appliance or bite splint.
* **Integrated Hardware**: The system includes a miniaturized electronic control unit, a drug reservoir (0.25–0.35 mL), and a Bluetooth-operated microcontroller for manual or sensor-guided activation.
* **Advanced Filtration**: To ensure patient safety, the reservoir is equipped with a selective membrane that allows the passage of free drug molecules while sequestering graphene particles, thereby eliminating systemic exposure risks.
* **Anatomical Integration**: The final prototype is miniaturized to fit comfortably within the sublingual lateral space, ensuring user acceptability and reproducible drug release.
### 4. Roadmap and Technical Objectives (TRL 4 to 6)
The project will advance the technology from laboratory validation (TRL 4) to a clinically relevant prototype (TRL 6).
* **Pharmaceutical Optimization**: Achieving a dispersion stability of $\ge95\%$ over 12 months and ensuring a mucosal apparent permeability of $P_{app} \ge 1 imes 10^{-6}$ cm/s.
* **Validation**: Stepwise testing involving synthetic mucosa, ex vivo porcine models, and in vivo rodent models of status epilepticus to confirm pharmacokinetics and a $\ge90\%$ seizure termination success rate.
* **Closed-Loop Evolution**: While the initial version utilizes manual triggering, the project establishes a pathway for autonomous intervention by interfacing with commercially available wearable EEG sensors.
* **Business Development**: Establishment of an academic spin-off company within the first year (M12) to manage intellectual property and commercialization.
### 5. Socio-Economic Impact
CLUSTREL represents a paradigm shift in emergency epilepsy management:
* **Autonomy**: It reduces dependence on caregivers and eliminates the need for invasive administration routes (rectal or intravenous).
* **Healthcare Sustainability**: By preventing the escalation of seizures, the system reduces emergency visits and ICU costs, with estimated savings between €2,000 and €6,000 per episode.
* **Market Potential**: CLUSTREL enters a global seizure-rescue market valued at over USD 3 billion, utilizing a revenue model based on device sales and recurring drug refills.